KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) EBT (2016 - 2026)

Pfizer has reported EBT over the past 18 years, most recently at $3.2 billion for Q1 2026.

  • Quarterly EBT rose 13.82% to $3.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.9 billion through Mar 2026, down 26.92% year-over-year, with the annual reading at $7.5 billion for FY2025, 6.27% down from the prior year.
  • EBT was $3.2 billion for Q1 2026 at Pfizer, up from -$1.6 billion in the prior quarter.
  • Over five years, EBT peaked at $11.4 billion in Q3 2022 and troughed at -$4.1 billion in Q4 2023.
  • The 5-year median for EBT is $3.2 billion (2026), against an average of $3.3 billion.
  • Year-over-year, EBT crashed 137.24% in 2023 and then soared 3055.34% in 2025.
  • A 5-year view of EBT shows it stood at $9.0 billion in 2022, then tumbled by 145.87% to -$4.1 billion in 2023, then skyrocketed by 214.19% to $4.7 billion in 2024, then tumbled by 134.83% to -$1.6 billion in 2025, then soared by 293.06% to $3.2 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's EBT are $3.2 billion (Q1 2026), -$1.6 billion (Q4 2025), and $3.3 billion (Q3 2025).